Clinical and Morphological Features of Extrapulmonary Small-Cell Cancer Abstract #2154

Introduction: Extrapulmonary Small-cell cancer (ESCC) is an extremely rare disease. Usually in the treatment of patients with ESCC approaches to the treatment of patients with small cell lung cancer (SCLC) are used.
Aim(s): To reveal clinical and morphological features of patients with ESCC in comparison with patients with SCLC. To assess the frequency of expression of the receptors for somatostatin in patients with ESCC and SCLC.
Materials and methods: a set of two groups of patients was performed: group A of 36 patients with ESCC. All patients with ESCC have studied for expression of somatostatin receptors 2 and 5 types, levels of serotonin, chromogranin A and NSE in the serum. All patients in the first line of therapy received treatment with etoposide and platinum preparations. Group B of 52 patients with SCLC. All patients underwent the study of expression of somatostatin receptors 2 and 5 types. Patients received treatment on the basis of etoposide and platinum preparations in first line of chemotherapy.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Alexey Ivanov

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1115 Cancer Stem Cells in Small Intestine Neuroendocrine Cell Line P-STS: Isolation and Molecular Characterisation
Introduction: Cancer stem cells (CSCs) represent a small subpopulation of tumour cells responsible for invasive tumour growth. Even though the presence of CSCs in neuroendocrine tumours is documented, their role in neuroendocrine tumourigenesis and metastasis is not defined as yet.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Florian Kleinegger
#1653 Expression and Clinical Significance of Somatostatin Receptor Subtype 2A in Small Cell Lung Carcinoma
Introduction: Somatostatin receptors (SSTRs) play a key role in the regulation of cell proliferation and have been identified in a proportion of aggressive poorly differentiated neuroendocrine neoplasms, including small cell lung carcinomas (SCLCs).
Conference: 14th Annual ENETS conference (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Vera Delektorskaya
#2141 Potential Role of SST5TMD4-Derived Peptides in the Malignancy of Neuroendocrine Tumors and Other Endocrine-Related Cancer Cells
Introduction: Extracellular fragments derived from membrane receptors can play relevant functional roles in certain tumoral pathologies and could provide novel diagnostic or therapeutic tools. We have identified a novel truncated somatostatin receptor type 5 variant, sst5TMD4, which is overexpressed and functionally active in different endocrine-related cancers, including neuroendocrine tumors (NETs). Interestingly, sst5TMD4 has 4 transmembrane domains and its C-terminal tail is consequently exposed towards the extracellular matrix, and could, therefore, be the substrate for proteolytic enzymes.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Sergio Pedraza-Arévalo
#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells
Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.
Conference: 17th Annual ENETS Conference (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Julie Refardt
#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Antongiulio Faggiano
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team